Manage cutaneous adverse effects associated with tumour necrosis factor inhibitors with topical corticosteroids and oral antibiotics

AbstractCutaneous adverse effects (CAEs), such as eczema, psoriasis, and skin infections, are common in patients receiving tumour necrosis factor inhibitors (TNFIs; e.g. adalimumab, etanercept and infliximab). Once a CAE is diagnosed, patients should receive appropriate dermatological care, as this may avoid cessation of TNFI therapy. Topical corticosteroids are the mainstay of therapy for numerous skin lesions, while oral antibiotics are effective in the treatment of superinfections.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research